{
    "clinical_study": {
        "@rank": "166299", 
        "arm_group": [
            {
                "arm_group_label": "fasted condition", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "fec condition", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of this study is to estimate the effect of food on sildenafil\n      pharmacokinetics after administration of Powder Oral Suspension (POS) formulation of\n      sildenafil citrate."
        }, 
        "brief_title": "Food Effect Study For New Formulation", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between the ages of 21 and 55 years\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).\n\n        Exclusion Criteria:\n\n          -  Baseline orthostatic hypotension defined as a \u226520 mm Hg reduction in systolic blood\n             pressure (SBP), a \u226510 mm Hg reduction in diastolic blood pressure (DBP) or the\n             development of significant postural symptoms (dizziness, lightheadedness, vertigo)\n             when going from the supine to standing position.\n\n          -  Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors\n             in any form on either a regular or intermittent basis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656798", 
            "org_study_id": "A1481313"
        }, 
        "intervention": [
            {
                "arm_group_label": "fasted condition", 
                "description": "2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose", 
                "intervention_name": "sildenafil citrate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "fec condition", 
                "description": "2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose", 
                "intervention_name": "sildenafil citrate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Sildenafil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 14, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481313&StudyName=Food%20Effect%20Study%20For%20New%20Formulation"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "188770"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study In Healthy Subjects Assessing The Pharmacokinetics And Safety Of Powder For Oral Suspension Of Sildenafil Citrate Administered Under Fasted And Fed Conditions", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of sildenafil", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - \u221e)] of sildenafil", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656798"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) of sildenafil", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)of sildenafil", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2) of sildenafil", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of UK-103,320", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - \u221e)] of UK-103,320", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of UK-103,320", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of UK-103,320", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2) of UK-103,320", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,14 hours post-dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}